Daiichi Sankyo Company (4568-TO)

QUOTE AND NEWS
The Economic Times  Jan 22  Comment 
Oscar Traders was one of 20 respondents linked to the brothers from whom Daiichi is trying to recover the money awarded to it by a Singapore arbitration tribunal last year.
The Hindu Business Line  Jan 17  Comment 
Daiichi Sankyo had sought a stay on plans by Malvinder and Shivinder Singh to sell over 26% in the healthcare firm
The Economic Times  Jan 16  Comment 
Daiichi’s move comes as the Singh brothers look to induct an investor in Fortis Healthcare.
GenEng News  Jan 10  Comment 
Kite Pharma has negotiated separate agreements with Fosun Pharma and with Daiichi Sankyo for the development of its lead CD19 chimeric antigen receptor (CAR) T-cell autologous cell therapy, axicabtagene ciloleucel (KTE-C19), in Japan and China,...
The Economic Times  Jan 2  Comment 
The company's product is a generic version of Daiichi Sankyo Inc's Evoxac capsules, it added.
The Economic Times  Dec 26  Comment 
Olmesartan medoximil tablets, generic version of Daiichi Sankyo's Benicar, are indicated for the treatment of hypertension, along with other anti-hypertensive agents.
The Economic Times  Nov 2  Comment 
Ajanta Pharma's Amlodipine + Olmesartan Medoxomil tablets are a generic version of Daiichi Sankyo Inc's Azor tablets​
newratings.com  Oct 31  Comment 
TOKYO (dpa-AFX) - Daiichi Sankyo Company Limited(DSKYF.PK)reported that its profit attributable to owners of the Company First Six Months of fiscal 2016 decreased by ¥21.7 billion, or 30.7% year on year, to ¥49.0 billion. The profit attributable...
The Hindu Business Line  Oct 27  Comment 
Sun Pharmaceutical Industries has launched generic versions of Daiichi Sankyo medicines, used in the treatment of high blood pressure, in the US market.In a BSE filing, Sun Pharmaceutical Industries ...





You may also be interested in articles related to Daiichi Sankyo Company (4568-TO):
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki